|
As vaccination for COVID continues to roll out this year, and in the future, it is less likely that corresponding vaccination can be maintained for kids age 6 months to 4 years of age. While the Food and Drug Administration’s Emergency Use Authorization (FDA EUA) restricts the Centers for Disease Control and Prevention’s (CDC) recommendation regarding what they can say about interchangeability of pediatric COVID vaccine products, providers should not miss an opportunity to vaccinate those who come seeking a COVID vaccination.
Providers should not be turning away patients or refusing to schedule vaccination appointments over this issue. CDC’s guidance when products are interchanged can be found at CDC: Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States. Some manufacturers’ vaccines may be more available than others, but availability of a particular brand of vaccine should not be a barrier to getting vaccinated for anyone.
On Oct. 3, the FDA amended the EUA of Novavax COVID-19 Vaccine, Adjuvanted to include the 2023-2024 formula. The original formula (monovalent) is no longer authorized for use in the United States. Refer to FDA: Novavax COVID-19 Vaccine, Adjuvanted for more information and links to fact sheets. We expect the CDC will make a recommendation and add information to the CDC: Interim Clinical Considerations for Use of COVID-19 Vaccines in the next few days. The Advisory Committee on Immunization Practices (ACIP) is not expected to meet.
Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) is authorized for use in individuals 12 years of age and older as follows:
-
Individuals previously vaccinated with any COVID-19 vaccine: one dose of Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) is administered at least 2 months after receipt of the last previous dose of an original monovalent (Original) or bivalent (Original and Omicron BA.4/BA.5) COVID-19 vaccine.
-
Individuals not previously vaccinated with any COVID-19 vaccine: two doses of Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) are administered three weeks apart.
-
Immunocompromised individuals: an additional dose of Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) may be administered at least 2 months following the last dose of a COVID-19 vaccine (2023-2024 Formula). Additional doses of Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) may be administered at the discretion of the healthcare provider, taking into consideration the individual’s clinical circumstances. The timing of the additional doses may be based on the individual’s clinical circumstances.
With the integration of the COVID-19 vaccine into the Minnesota Vaccine for Children (MnVFC) and Uninsured and Underinsured Adult Vaccine (UUAV) programs, we will be sunsetting the use of the V07 dose-level eligibility code when reporting COVID-19 vaccinations in MIIC. For more information on when to use which DLE codes, visit Dose-Level Eligibility Codes and Minnesota Vaccines for Children (MnVFC) and Uninsured and Underinsured Adult Vaccine (UUAV) Eligibility Status.
The Minnesota Immunization Information Connection (MIIC) team would like to thank you for your continued attention to data quality and timeliness. Your efforts have paid off, and as a result, Minnesotans have access to high-quality, up-to-date information about their vaccines. We appreciate all that you have done with data reporting throughout the past years. Thank you!
As we make the switch to commercialized COVID-19 vaccine product, we want to communicate how thankful we are to have worked with each one of you throughout this response. Together we have distributed almost 11 million doses of vaccine. This was truly a team effort, and we are so grateful for the work you have put in to ensure every Minnesotan has had the opportunity to be vaccinated.
|
